Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20826623 | 1.00 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL18174951 | 0.92 | PIK3CD (0.39) | PIK3CD | |
| SCHEMBL15249357 | 0.86 | PIK3CD (0.52) | PIK3CD | |
| SCHEMBL19701856 | 0.86 | PIK3CD (0.52) | PIK3CD | |
| SCHEMBL25768205 | 0.86 | PIK3CD (0.52) | PIK3CD | |
| SCHEMBL4546579 | 0.86 | PIK3CD (0.52) | PIK3CD | |
| SCHEMBL25767771 | 0.86 | PIK3CD (0.52) | PIK3CD | |
| SCHEMBL25081340 | 0.84 | PIK3CD (0.36) | PIK3CD | |
| SCHEMBL18294309 | 0.84 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL18118184 | 0.82 | PIK3CD (0.43) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240208909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024138206-A1 | FLUOROPYRIDOPYRIMIDINE AND FLUOROQUINAZOLINE DERIVATIES AND METHODS OF USE THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240208909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024050742-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20150079081-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2015019365-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2015-02-12 | — | — | WO | disclosed |
| US-20140343032-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | PIK3CD 162/4885 |
| US-20140343032-A1 | NOVEL 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2D6, TPMT | PIK3CD 3536/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | PIK3CD 1521/4885 |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | PIK3CD 3/4885 |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | PIK3CD 2/4885 |
| US-20150079081-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | PIK3CD 17/4885 |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | PIK3CD 2657/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CD 146/4885 |
| US-20240208909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES HAVING SOS1 INHIBITION ACTIVITIES AND USES THEREOF | SOS1, SOS2, IQGAP1 | PIK3CD 1200/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | PIK3CD 3/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | PIK3CD 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.